After AstraZeneca disclosed Wainua’s failure in ATTR-CM, Alnylam moved to defend its RNAi “silencer” approach, arguing the clinical results do not negate the broader value proposition for its marketed program Amvuttra or the next-generation therapy nucresiran. The debate among analysts has pivoted to treatment sequencing and whether stabilizers already address the underlying pathobiology sufficiently to reduce incremental benefit from gene-silencing therapies. Alnylam’s response frames the issue as one of patient selection and regimen context rather than a modality-wide setback. For the broader RNAi sector, the exchange highlights how single late-stage outcomes can rapidly reshape confidence in trial design and label expansion strategies across multiple programs.